Akari Therapeutics, Plc (AKTX) |
1.185 0.015 (1.3%) 04-26 15:59 |
Open: | 1.185 |
High: | 1.2 |
Low: | 1.17 |
Volume: | 10,002 |
Market Cap: | 8(M) |
PE Ratio: | -0.58 |
Exchange: | NASDAQ Capital Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 1.90 |
Resistance 1: | 1.59 |
Pivot price: | 1.21 |
Support 1: | 1.08 |
Support 2: | 0.90 |
52w High: | 5.5 |
52w Low: | 1.078 |
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
EPS | -16800000.000 |
Book Value | 0.000 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | 0.00 |
Return on Assets (ttm) | -115.5 |
Return on Equity (ttm) | -1.0 |
Mon, 15 Apr 2024
Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024 - GlobeNewswire
Tue, 02 Apr 2024
Insiders Who Purchased US$1.43m Of Akari Therapeutics Stock May Not Have Expected 21% Tumble - Simply Wall St
Mon, 01 Apr 2024
Akari Therapeutics Insider Ups Holding By 69% During Year - Yahoo Finance
Mon, 01 Apr 2024
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights - Yahoo Finance
Tue, 05 Mar 2024
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AKTX, HES, TGAN, NS - PR Newswire
Tue, 05 Mar 2024
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline ... - GlobeNewswire
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |